Evidence map›Paper›PMID 38409107›Full record

ArticleCell death & disease2024

SPOP point mutations regulate substrate preference and affect its function.

Yanran Deng, Wenhao Ding, Kaize Ma, Meixiao Zhan, Li Sun, Zizhang Zhou, Ligong Lu

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 12 citations in OpenAlex.

  1. High-throughput screening identifies a critical role of the SPOP-PABPC1 axis in lung adenocarcinoma progression.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Molecular insights for the tumor suppressor role of SPOP in prostate cancer.Biochimica et biophysica acta. Reviews on cancer · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Yanran DengJiangsu Key laboratory of Drug Screening, China Pharmaceutical University, 210009, Nanjing, China.
Wenhao DingCollege of Life Sciences, Shandong Agricultural University, 271018, Tai'an, China.
Kaize MaCollege of Life Sciences, Shandong Agricultural University, 271018, Tai'an, China.
Meixiao ZhanGuangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), 519000, Zhuhai, Guangdong, China.
Li SunJiangsu Key laboratory of Drug Screening, China Pharmaceutical University, 210009, Nanjing, China. sunli@cpu.edu.cn.ORCID 0000-0002-0849-1081
Zizhang ZhouKey Laboratory of Biodiversity Conservation and Bioresource Utilization of Jiangxi Province, College of Life Sciences, Jiangxi Normal University, 330022, Nanchang, China. zhouzz@sdau.edu.cn.ORCID 0000-0001-5883-8218
Ligong LuGuangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), 519000, Zhuhai, Guangdong, China. luligong1969@jnu.edu.cn.ORCID 0000-0003-1405-0052
China Pharmaceutical University · CNJinan University · CNShandong Agricultural University · CNJiangxi Normal University · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 31802012National Natural Science Foundation of China (National Science Foundation of China) 31922011National Natural Science Foundation of China (National Science Foundation of China) 32270522National Natural Science Foundation of China (National Science Foundation of China) 82230067National Natural Science Foundation of China (National Science Foundation of China) 82272668
6 · The paper itself

Abstract

The adaptor SPOP recruits substrates to CUL3 E3 ligase for ubiquitination and degradation. Structurally, SPOP harbors a MATH domain for substrate recognition, and a BTB domain responsible for binding CUL3. Reported point mutations always occur in SPOP's MATH domain and are through to disrupt affinities of SPOP to substrates, thereby leading to tumorigenesis. In this study, we identify the tumor suppressor IRF2BP2 as a novel substrate of SPOP. SPOP enables to attenuate IRF2BP2-inhibited cell proliferation and metastasis in HCC cells. However, overexpression of wild-type SPOP alone suppresses HCC cell proliferation and metastasis. In addition, a HCC-derived mutant, SPOP-M35L, shows an increased affinity to IRF2BP2 in comparison with wild-type SPOP. SPOP-M35L promotes HCC cell proliferation and metastasis, suggesting that M35L mutation possibly reprograms SPOP from a tumor suppressor to an oncoprotein. Taken together, this study uncovers mutations in SPOP's MATH lead to distinct functional consequences in context-dependent manners, rather than simply disrupting its interactions with substrates, raising a noteworthy concern that we should be prudent to select SPOP as therapeutic target for cancers.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsCullin ProteinsHumansNuclear ProteinsPoint MutationRepressor ProteinsUbiquitinationCullin ProteinsNuclear ProteinsRepressor ProteinsSPOP protein, human

Identifiers

PMID38409107
PMCPMC10897488
OpenAlexW4392163071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.